Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- PMDA Taking Public Comments on Proposed Revisions of the Japanese Pharmacopoeia
December 12, 2012
- Generic Drug Use Rising at DPC Hospitals: MHLW
December 11, 2012
- MHLW Puzzled at “Opaque” GRU Recommendation after Project Screening
December 10, 2012
- Long-Listed Products Not Granted Premium Should Be Exempted from New Rule: FPMAJ’s Kamoya
December 10, 2012
- MHLW Proposes Salary Survey with Employees of Pharmacies
December 10, 2012
- CSIMC Nixes Industry’s Call for “Hold” on Further Price Cuts on Long-Listed Drugs
December 6, 2012
- Japan “Not Ready” for Reference Price System at the Present Time: Prof. Sakamaki of Meijo University
December 6, 2012
- CSIMC Subcommittee Agrees on Introduction of New Price-Cut Rule for Long-Listed Products
December 6, 2012
- MHLW Asks to Revise Precautions Section of Package Inserts for Poteligeo, Telavic
December 6, 2012
- PFSB to Initiate Epidemiological Study of Vaccination and Sudden Infant Death
December 5, 2012
- PAFSC’s 1st Committee on New Drugs Recommends Orphan Drug Designation for 2 Products Including Kyowa Kirin’s Cinacalcet
December 4, 2012
- 3 Products Including Daiichi Sankyo’s Calblock Classified as Category I
December 4, 2012
- PAFSC’s 1st Committee Recommends Approval for Factor Xa Inhibitor Apixaban
December 3, 2012
- MHLW to Conduct Field Study for Japanese Version of “Compassionate Use” System
December 3, 2012
- Price Agreement Rates for JPWA, NPhA Member Companies Just 11% at End of September: Distribution Council
December 3, 2012
- Price Agreement Rate at 43.5% in September; Down 3.2 Points from 2 Years Ago: MHLW Survey
December 3, 2012
- 6 APIs Including Taiho’s Aloxi IV Infusion Bag Added to NHI Price List
December 3, 2012
- PAFSC’s 2nd Committee Recommends Approval for Allegra-Pseudoephedrine Combination Drug Dellegra
November 30, 2012
- Expert Subcommittee to Discuss New Targets for Generic Drugs at Next Meeting
November 30, 2012
- MHLW Safety Info. Calls for Caution on Pulmonary Hypertension Associated with Glivec
November 30, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…